DNA Ginkgo Bioworks Holdings Inc

  1. Stocks
  2. Healthcare
  3. NYSE: DNA

Price (delayed)

$8.58

Market cap

$577.78M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.01

Enterprise value

$812.79M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 29
Highlights
The EPS rose by 14% year-on-year and by 7% since the previous quarter
DNA's quick ratio is up by 11% since the previous quarter and by 7% year-on-year
The gross profit has dropped by 51% year-on-year and by 15% since the previous quarter
The revenue has declined by 47% year-on-year and by 15% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of DNA

DNA stock price

How has the Ginkgo Bioworks Holdings stock price performed over time
Intraday
-8.43%
1 week
21.53%
1 month
15.95%
1 year
-30.53%
YTD
3.25%
QTD
-13.42%

Financial performance

How have Ginkgo Bioworks Holdings's revenue and profit performed over time
Revenue
$111.86M
Gross profit
$86.94M
Operating income
-$290.69M
Net income
-$290.8M
Gross margin
77.7%
Net margin
-260%
DNA's operating margin has plunged by 83% YoY and by 17% from the previous quarter
The net margin has dropped by 73% year-on-year and by 12% since the previous quarter
The gross profit has dropped by 51% year-on-year and by 15% since the previous quarter
The revenue has declined by 47% year-on-year and by 15% since the previous quarter

Price vs fundamentals

How does DNA's price correlate with its fundamentals

Growth

What is Ginkgo Bioworks Holdings's growth rate over time

Valuation

What is Ginkgo Bioworks Holdings stock price valuation
P/E
N/A
P/B
1.33
P/S
4.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.27
The EPS rose by 14% year-on-year and by 7% since the previous quarter
The price to book (P/B) is 46% lower than the 5-year quarterly average of 2.7 but 22% higher than the last 4 quarters average of 1.2
The equity is down by 31% year-on-year and by 5% since the previous quarter
The stock's price to sales (P/S) is 55% less than its 5-year quarterly average of 11.6 but 30% more than its last 4 quarters average of 4.0
The revenue has declined by 47% year-on-year and by 15% since the previous quarter

Efficiency

How efficient is Ginkgo Bioworks Holdings business performance
The return on sales has dropped by 73% year-on-year and by 12% since the previous quarter
The ROE has contracted by 33% YoY and by 5% from the previous quarter
The company's return on assets fell by 15% YoY
The company's return on invested capital rose by 9% YoY

Dividends

What is DNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DNA.

Financial health

How did Ginkgo Bioworks Holdings financials performed over time
Ginkgo Bioworks Holdings's total assets is 74% higher than its total liabilities
Ginkgo Bioworks Holdings's total assets has decreased by 20% YoY and by 4.2% QoQ
Ginkgo Bioworks Holdings's current ratio has decreased by 16% YoY and by 11% from the previous quarter
The debt is 3.8% smaller than the equity
The debt to equity has grown by 37% YoY and by 3.2% from the previous quarter
The equity is down by 31% year-on-year and by 5% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.